author-photo

Margaret Green

University of Chicago

24

Papers

640

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

2018 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (34)
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

2018 Experimental hematology & oncology
Show All
- Source
- Cite
- Save
Citations (13)
Therapy-related myeloid neoplasms (t-MN) in 84 patients (pts) following radiation therapy (RT) only.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia

2015 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (8)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

2014 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (83)
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

2012 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (18)
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant

2010 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (16)
High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

2009 Blood
Show All
- Source
- Cite
- Save
Citations (2)